U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C7H8N4O2
Molecular Weight 180.164
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THEOPHYLLINE ANHYDROUS

SMILES

CN1C2=C(N=CN2)C(=O)N(C)C1=O

InChI

InChIKey=ZFXYFBGIUFBOJW-UHFFFAOYSA-N
InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9676340 | https://www.ncbi.nlm.nih.gov/pubmed/27713276

Since its discovery as component of the tea leaf by Albert Kossel in 1888, the history of theophylline (CAS 58-55-9) has been a long and successful one. At the turn of the century, theophylline became less expensive due to chemical synthesis and was primarily used as diuretic in subsequent years. It was Samuel Hirsch who discovered the bronchospasmolytic effect of theophylline in 1992, however, despite this pioneering discovery theophylline continued to be used primarily as diuretic and cardiac remedy. The molecular mechanism of bronchodilatation is inhibition of phosphodiesterase(PDE)3 and PDE4, but the anti-inflammatory effect may be due to histone deacetylase (HDAC) activation, resulting in switching off of activated inflammatory genes. Theophylline is indicated for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

Originator

Curator's Comment: Albert Kossel discovered theophylline as a component of the tea leaf

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

Approved Use

Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

Launch Date

1982
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.3 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THEOPHYLLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
95.5 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THEOPHYLLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.51 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THEOPHYLLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
41%
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THEOPHYLLINE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
20 mg/mL steady, intravenous
Highest studied dose
Dose: 20 mg/mL
Route: intravenous
Route: steady
Dose: 20 mg/mL
Sources:
unhealthy, 39 years (51 % < 40 years)
Health Status: unhealthy
Age Group: 39 years (51 % < 40 years)
Sex: M+F
Sources:
Disc. AE: Vomiting...
Other AEs: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (grade 3, 5.75%)
Other AEs:
Vomiting (12.64%)
Sources:
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
Disc. AE: Gastrointestinal discomfort, Supraventricular tachycardia...
Other AEs: Tremor, Nervousness...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal discomfort (grade 3, 16.7%)
Supraventricular tachycardia (grade 3, 16.7%)
Other AEs:
Tremor (16.7%)
Nervousness (16.7%)
Dysrhythmias (grade 1, 16.7%)
Sources:
800 mg single, oral
Recommended
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M
Sources:
800 mg 1 times / day steady, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: steady
Dose: 800 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Other AEs: Generalized epileptic seizure, Cardiac arrhythmias...
Other AEs:
Generalized epileptic seizure (grade 4-5)
Cardiac arrhythmias (grade 4-5)
Calcium increased serum
Creatine kinase increased
Blood myoglobin increased
Leukocyte count increased
Serum phosphate decreased
Magnesium serum decreased
Acute myocardial infarction
Obstructive uropathy
Cardio-respiratory arrest (grade 5)
Hypoxic encephalopathy (grade 5)
Sources:
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Other AEs: Vomiting, Hypokalemia...
Other AEs:
Vomiting (30%)
Hypokalemia (44%)
Hyperglycemia (18%)
Acid-base balance abnoraml (9%)
Sinus tachycardia (100%)
Supraventricular tachycardia (12%)
Premature ventricular ectopic beats (10%)
Atrial flutter/ fibrillation (12%)
Multifocal atrial tachycardia (2%)
Hemodynamic instability (40%)
Tremor (16%)
Seizures (14%)
Sources:
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Other AEs: Vomiting, Abdominal pain...
Other AEs:
Vomiting (61%)
Abdominal pain (12%)
Diarrhea (14%)
Hematemesis (2%)
Hypokalemia (43%)
Acid-base balance abnoraml (9%)
Sinus tachycardia (62%)
Supraventricular tachycardia (14%)
Premature ventricular ectopic beats (19%)
Hypotension (8%)
Nervousness (21%)
Tremor (14%)
Disorientation (11%)
Seizures (5%)
Sources:
10 mg/kg single, oral
Overdose
unknown
Other AEs: Vomiting, Hypokalemia...
Other AEs:
Vomiting (73%)
Hypokalemia (85%)
Hyperglycemia (98%)
Acid-base balance abnoraml (34%)
Sinus tachycardia (100%)
Supraventricular tachycardia (2%)
Premature ventricular ectopic beats (3%)
Atrial flutter/ fibrillation (1%)
Hemodynamic instability (7%)
Tremor (38%)
Seizures (5%)
Sources:
10 mg/kg single, oral
Overdose
unknown
Other AEs: Abdominal pain, Rhabdomyolysis...
Other AEs:
Abdominal pain (21%)
Rhabdomyolysis (7%)
Hypotension (21%)
Nervousness (64%)
Disorientation (7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Vomiting 12.64%
20 mg/mL steady, intravenous
Highest studied dose
Dose: 20 mg/mL
Route: intravenous
Route: steady
Dose: 20 mg/mL
Sources:
unhealthy, 39 years (51 % < 40 years)
Health Status: unhealthy
Age Group: 39 years (51 % < 40 years)
Sex: M+F
Sources:
Vomiting grade 3, 5.75%
Disc. AE
20 mg/mL steady, intravenous
Highest studied dose
Dose: 20 mg/mL
Route: intravenous
Route: steady
Dose: 20 mg/mL
Sources:
unhealthy, 39 years (51 % < 40 years)
Health Status: unhealthy
Age Group: 39 years (51 % < 40 years)
Sex: M+F
Sources:
Nervousness 16.7%
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
Tremor 16.7%
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
Dysrhythmias grade 1, 16.7%
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
Gastrointestinal discomfort grade 3, 16.7%
Disc. AE
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
Supraventricular tachycardia grade 3, 16.7%
Disc. AE
1200 mg 1 times / day steady, oral
Recommended
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 ± 9
Health Status: unhealthy
Age Group: 66 ± 9
Sex: M+F
Sources:
Acute myocardial infarction
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Blood myoglobin increased
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Calcium increased serum
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Creatine kinase increased
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Leukocyte count increased
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Magnesium serum decreased
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Obstructive uropathy
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Serum phosphate decreased
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Cardiac arrhythmias grade 4-5
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Generalized epileptic seizure grade 4-5
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Cardio-respiratory arrest grade 5
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hypoxic encephalopathy grade 5
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Premature ventricular ectopic beats 10%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Sinus tachycardia 100%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Atrial flutter/ fibrillation 12%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Supraventricular tachycardia 12%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Seizures 14%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Tremor 16%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hyperglycemia 18%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Multifocal atrial tachycardia 2%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Vomiting 30%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hemodynamic instability 40%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hypokalemia 44%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Acid-base balance abnoraml 9%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Disorientation 11%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Abdominal pain 12%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Diarrhea 14%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Supraventricular tachycardia 14%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Tremor 14%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Premature ventricular ectopic beats 19%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hematemesis 2%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Nervousness 21%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hypokalemia 43%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Seizures 5%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Vomiting 61%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Sinus tachycardia 62%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Hypotension 8%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Acid-base balance abnoraml 9%
1600 mg 1 times / day multiple, oral
Overdose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources:
unhealthy
Atrial flutter/ fibrillation 1%
10 mg/kg single, oral
Overdose
unknown
Sinus tachycardia 100%
10 mg/kg single, oral
Overdose
unknown
Supraventricular tachycardia 2%
10 mg/kg single, oral
Overdose
unknown
Premature ventricular ectopic beats 3%
10 mg/kg single, oral
Overdose
unknown
Acid-base balance abnoraml 34%
10 mg/kg single, oral
Overdose
unknown
Tremor 38%
10 mg/kg single, oral
Overdose
unknown
Seizures 5%
10 mg/kg single, oral
Overdose
unknown
Hemodynamic instability 7%
10 mg/kg single, oral
Overdose
unknown
Vomiting 73%
10 mg/kg single, oral
Overdose
unknown
Hypokalemia 85%
10 mg/kg single, oral
Overdose
unknown
Hyperglycemia 98%
10 mg/kg single, oral
Overdose
unknown
Abdominal pain 21%
10 mg/kg single, oral
Overdose
unknown
Hypotension 21%
10 mg/kg single, oral
Overdose
unknown
Nervousness 64%
10 mg/kg single, oral
Overdose
unknown
Disorientation 7%
10 mg/kg single, oral
Overdose
unknown
Rhabdomyolysis 7%
10 mg/kg single, oral
Overdose
unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Resin hemoperfusion as treatment for theophylline-induced seizures.
1979 Jun
Successful resuscitation of a verapamil-intoxicated patient with percutaneous cardiopulmonary bypass.
1999 Dec
[A case of acute renal failure with rhabdomyolysis caused by the interaction of theophylline and clarithromycin].
1999 Jun
Effects of Saiko-ka-ryukotsu-borei-to, a Japanese Kampo medicine, on tachycardia and central nervous system stimulation induced by theophylline in rats and mice.
1999 Mar
Gamma-aminobutyric acid and glutamic acid receptors may mediate theophylline-induced seizures in mice.
1999 Mar
Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells.
1999 Nov
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
1999 Nov
[A case of acute theophylline intoxication with repeated status convulsivus].
1999 Nov
Theophylline, aminophylline, caffeine and analogues for acute ischaemic stroke.
2000
Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.
2000 Apr
Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects.
2001
A novel method for measuring gel strength of controlled release hydrogel tablets using a cone/plate rheometer.
2001
Rat ventral prostate xanthine oxidase bioactivation of ethanol to acetaldehyde and 1-hydroxyethyl free radicals: analysis of its potential role in heavy alcohol drinking tumor-promoting effects.
2001
Caffeine metabolism before and after liver transplantation.
2001 Feb
Therapeutic options for the management of patients with cardiac syndrome X.
2001 Feb
Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis.
2001 Feb
Mechanism of prolonged vasorelaxation to ATP in the rat isolated mesenteric arterial bed.
2001 Feb
Facilitative effects of an adenosine A1/A2 receptor blockade on spatial memory performance of rats: selective enhancement of reference memory retention during the light period.
2001 Jan 8
Adenosine diphosphate ribose dilates bovine coronary small arteries through apyrase- and 5'-nucleotidase-mediated metabolism.
2001 Jan-Feb
Purinergic contribution to circulatory, metabolic, and adrenergic responses to acute hypoxemia in fetal sheep.
2001 Mar
Cytosolic xanthine oxidoreductase mediated bioactivation of ethanol to acetaldehyde and free radicals in rat breast tissue. Its potential role in alcohol-promoted mammary cancer.
2001 Mar 7
Patents

Sample Use Guides

For a given population there is no single theophylline dose that will provide both safe and effective serum concentrations for all patients. The dose of theophylline must be individualized on the basis of serum theophylline concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk of adverse effects.
Route of Administration: Other
1 mM theophylline inhibited histamine release from human skin mast cells
Name Type Language
THEOPHYLLINE ANHYDROUS
HSDB  
Common Name English
THEOPHYLLINE MELTING POINT STANDARD
USP-RS  
Preferred Name English
PENTOXIFYLLINE IMPURITY C [EP IMPURITY]
Common Name English
Theophylline [WHO-DD]
Common Name English
1,3-DIMETHYLXANTHINE
Systematic Name English
THEOPHYLLINE,ANHYDROUS [VANDF]
Common Name English
THEOPHYLLINE [USP-RS]
Common Name English
THEOPHYLLINE [MI]
Common Name English
THEOPHYLLINE, ANHYDROUS
Common Name English
NSC-2066
Code English
THEOPHYLLINE ANHYDROUS [HSDB]
Common Name English
DIMENHYDRINATE IMPURITY A [EP IMPURITY]
Common Name English
DOXOPHYLLINE METABOLITE M3
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C319
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
NCI_THESAURUS C221
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
NDF-RT N0000008118
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
NDF-RT N0000175790
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
WHO-ATC R03DB02
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
NDF-RT N0000008118
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
Code System Code Type Description
NSC
2066
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
EVMPD
SUB40136
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
SMS_ID
100000091484
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
DRUG BANK
DB00277
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
FDA UNII
0I55128JYK
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
MERCK INDEX
m10706
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY Merck Index
HSDB
3399
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
RXCUI
91178
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY RxNorm
DAILYMED
0I55128JYK
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
CAS
58-55-9
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
EPA CompTox
DTXSID5021336
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
CHEBI
28177
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-385-7
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
EVMPD
SUB15516MIG
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
PUBCHEM
2153
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
NCI_THESAURUS
C61968
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY
RS_ITEM_NUM
1653117
Created by admin on Mon Mar 31 18:13:42 GMT 2025 , Edited by admin on Mon Mar 31 18:13:42 GMT 2025
PRIMARY